IRWD

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $1M315.6k shares TrimQ1 2026 $145k $3.51 $3.87
Jim SimonsRenaissance Technologies $28M8.1M shares AddQ1 2026 $644k $3.51 $3.87
Ken FisherFisher Asset Management $-33.7K ExitQ1 2026 $34k -- $3.87
Ken GriffinCitadel Advisors $358.9K AddQ4 2025 $359k -- $3.87
Jim SimonsRenaissance Technologies $16.7M AddQ4 2025 $17M -- $3.87
Chuck RoyceRoyce & Associates $-393.8K ExitQ4 2025 $394k -- $3.87

Insider Trades

Name	Value	Action	Price	Last Price
Denner Alexander JDirector $21M6.7M shares SellMar 17, 2026 $3.05 $3.87
Denner Alexander JDirector $19k5.8k shares SellMar 17, 2026 $3.31 $3.87
MCCOURT Thomas ADirector, Officer: Chief Executive Officer $379k103.5k shares SellFeb 24, 2026 $3.66 $3.87
MCCOURT Thomas ADirector, Officer: Chief Executive Officer $361k94.8k shares SellFeb 23, 2026 $3.81 $3.87
John MinardoChief Legal Officer $70k19.1k shares SellFeb 24, 2026 $3.66 $3.87
John MinardoChief Legal Officer $66k17.4k shares SellFeb 23, 2026 $3.81 $3.87

News

businesswire.comIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conferencebusinesswire.comMay 28

zacks.comIRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Usezacks.comMay 28

gurufocus.comFDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)gurufocus.comMay 27

businesswire.comFDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)businesswire.comMay 27

seekingalpha.comIronwood Pharmaceuticals: A Contrarian Buy Opportunityseekingalpha.comMay 21

Trade IRWD

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.

CEO: Thomas A. McCourt
IPO Date: Feb 3, 2010

Market Data

Open: $3.27
High: $3.39
Low: $3.15
Volume: 2M
52W High: $5.78
52W Low: $0.58

Valuation

Market Cap: $530.1M
Enterprise Value: $906.9M

Financials

Free Cash Flow: $127M
Revenue: $296.2M
Net Income: $24M
Cash: $215.5M
Debt: $597.8M

Events

EarningsAug 6

EPS est. 0.26